In vitro, the derivative of Zilovertamab, D10, inhibited sphere formation, increased methotrexate sensitivity and reduced expression of SOX2 demonstrating the role of ROR1 in osteosarcoma CSCs and chemoresistance [13]. Here, ROR1 is linked to osteosarcoma.